{"commentary":{"count":281,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":126,"youtube":85,"podcast":63,"x_video":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05382299\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ASCENT-03","nct_id":"NCT05382299","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ascent-03-nct05382299. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ASCENT-03","arms":[{"description":"Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.","label":"Sacituzumab Govitecan-hziy (SG)","type":"EXPERIMENTAL"},{"description":"Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens:\n\n* Paclitaxel 90 mg/m\\^2 on Days 1, 8, and 15 of a 28-day cycle\n* Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 of a 28-day cycle\n* Gemcitabine 1000 mg/m\\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle","label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-07","type":"ESTIMATED"},"conditions":["Triple Negative Breast Cancer","PD-L1 Negative"],"enrollment":{"count":623,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan-hziy","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"nab-Paclitaxel","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2026-04-06","lead_sponsor":"Gilead Sciences","official_title":"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"Randomization up to approximately 57 months"}],"references":[{"citation":"Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19.","pmid":"41124233","type":"DERIVED"}],"start_date":{"date":"2022-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05382299"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ascent-03-nct05382299"}